$GSK 4 SEC Filings

Filed On	Filing
15 Dec 2025	Form 4: Gsk plc, 10% owner · Wave Life Sciences, Inc. Bought 1,470,000 shares ($27.9M)
01 Oct 2024	Form 4: Gsk plc, 10% owner · Wave Life Sciences, Inc. Bought 2,791,930 shares ($22.3M)
30 Jan 2024	Form 4: Gsk plc, 10% owner · Wave Life Sciences, Inc. Bought 3,300,000 shares ($16.5M)
20 Sep 2022	Form 4: Gsk Plc, Former 10% Owner · Theravance Biopharma, Inc. Disposed of 9,644,807 shares (Other Transaction) ($94M) · Acquired 0 Exchangeable Senior Notes due 2023 (Other Transaction)
06 Jul 2021	Form 4: Glaxosmithkline Plc, 10% owner · Cvrx, Inc Received 700,772 shares by conversion · Bought 275,000 shares ($4.95M)
23 Jun 2021	Form 4: Glaxosmithkline Plc, 10% owner · Lyell Immunopharma, Inc. Received 30,253,189 shares by conversion
24 May 2021	Form 4: Glaxosmithkline Plc, 10% owner · Innoviva, Inc. Sold 32,005,260 shares ($392M)
19 Feb 2021	Form 4: Glaxosmithkline Plc, Director · Decibel Therapeutics, Inc. Received 1,033,663 shares by conversion · Bought 150,000 shares ($2.7M)
18 Sep 2020	Form 4: Glaxosmithkline Plc, 10% owner · Bicycle Therapeutics PLC Sold 1,597 shares ($30.8K) · Sold 3,147 shares ($61K)
30 Jul 2020	Form 4: Glaxosmithkline Plc, 10% owner · GENOCEA BIOSCIENCES, INC. Bought 1,260,504 shares ($2.84M) · Acquired 1,260,504 Warrant (Open Market Purchase) ($158K)
22 Jul 2020	Form 4: Glaxosmithkline Plc, Director · Pandion Therapeutics, Inc. Granted 13,997 Stock Option (right to buy) · Received 1,887,193 shares by conversion · Bought 361,111 shares ($6.5M)
16 Jul 2020	Form 4: Glaxosmithkline Plc, Director · Nkarta, Inc. Received 2,317,399 shares by conversion · Bought 833,333 shares ($15M) · Granted 10,700 Stock Option (right to buy)
22 Jun 2020	Form 4: Glaxosmithkline Plc, 10% owner · Theravance Biopharma, Inc. Disposed of 0 Exchangeable Note (Open Market Sale)
26 May 2020	Form 4: Glaxosmithkline Plc, Director · Turning Point Therapeutics, Inc. Bought 83,333 shares ($5M)
21 May 2020	Form 4: Glaxosmithkline Plc, 10% owner · Progyny, Inc. Sold 4,000,000 shares ($103M)
31 Oct 2019	Form 4: Glaxosmithkline Plc, 10% owner · Progyny, Inc. Received 9,821,190 shares by conversion
22 Oct 2019	Form 4: Glaxosmithkline Plc, Former 10% Owner · Principia Biopharma Inc. Bought 357,142 shares ($10M)
12 Sep 2019	Form 4: Glaxosmithkline Plc, Director · Turning Point Therapeutics, Inc. Bought 177,777 shares ($8M)
24 Jul 2019	Form 4: Glaxosmithkline Plc, 10% owner · Fulcrum Therapeutics, Inc. Received 1,785,714 shares by conversion
02 Jul 2019	Form 4: Glaxosmithkline Plc, Director · Morphic Holding, Inc. Received 2,300,439 shares by conversion · Bought 333,333 shares ($5M)

Comments